Andreas Pinter

Also affiliated with Fraunhofer Institute for Translational Medicine and Pharmacology, University Hospital Frankfurt, Hidradenitis Suppurativa Foundation

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)”.

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

British Journal of Dermatology(2023)10.1093/bjd/ljad252

N/A

0.662DataRank · unranked

22 citations

Jerry Bagel, Stephen K. Tyring, Hwanhee Hong, Lev Pavlovsky, Ronald Vender +11 more

Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial

British Journal of Dermatology(2025)10.1093/bjd/ljaf398

N/A

0.208DataRank · unranked

3 citations

Gregor B. E. Jemec, Errol P. Prens, Niels C. Riedemann, Isabella Otto, Jamie Weisman +20 more